PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.17M | 5.52M | 3.49M | 3.18M | 2.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.17M | 5.52M | 3.49M | 3.18M | 2.79M |
| Cost of Revenue | 3.16M | 3.39M | 2.06M | 1.91M | 1.66M |
| Gross Profit | 2.01M | 2.13M | 1.42M | 1.26M | 1.13M |
| SG&A Expenses | 1.79M | 2.34M | 1.62M | 1.37M | 842.00K |
| Depreciation & Amortization | 253.40K | 245.20K | 161.40K | 136.30K | 130.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.21M | 5.97M | 3.85M | 3.42M | 2.63M |
| Operating Income | -36.90K | -456.50K | -362.20K | -239.00K | 159.00K |
| Income Before Tax | 85.20K | -388.80K | -310.80K | -164.60K | 252.30K |
| Income Tax Expenses | -6.10K | 243.50K | -13.70K | 114.20K | 75.10K |
| Earnings from Continuing Operations | 91.30K | -632.30K | -297.10K | -278.80K | 177.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.50K | -21.70K | -13.30K | 1.20K | -8.60K |
| Net Income | 77.80K | -654.00K | -310.40K | -277.60K | 168.60K |
| EBIT | -36.90K | -456.50K | -362.20K | -239.00K | 159.00K |
| EBITDA | 184.60K | -245.00K | -219.20K | -118.90K | 289.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 174.08M | 148.67M | 117.30M | 117.30M | 117.30M |
| Average Diluted Shares Outstanding | 183.42M | 148.67M | 117.30M | 117.30M | 125.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |